Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros

Base de dados
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
Acta Neuropathol ; 133(5): 785-807, 2017 05.
Artigo em Inglês | MEDLINE | ID: mdl-28070672

RESUMO

Progranulin (PGRN) is implicated in Alzheimer's disease (AD) as well as frontotemporal lobar degeneration. Genetic studies demonstrate an association of the common GRN rs5848 variant that results in reduced PGRN levels with increased risk for AD. However, the mechanisms by which PGRN reduction from the GRN AD risk variant or mutation exacerbates AD pathophysiology remain ill defined. Here, we show that the GRN AD risk variant has no significant effects on florbetapir positron emission tomographic amyloid imaging and cerebrospinal fluid (CSF) Aß levels, whereas it is associated with increased CSF tau levels in human subjects of the Alzheimer's disease neuroimaging initiative studies. Consistent with the human data, subsequent analyses using the APPswe/PS1ΔE9 (APP/PS1) mouse model of cerebral amyloidosis show that PGRN deficiency has no exacerbating effects on Aß pathology. In contrast and unexpectedly, PGRN deficiency significantly reduces diffuse Aß plaque growth in these APP/PS1 mice. This protective effect is due, at least in part, to enhanced microglial Aß phagocytosis caused by PGRN deficiency-induced expression of TYROBP network genes (TNG) including an AD risk factor Trem2. PGRN-deficient APP/PS1 mice also exhibit less severe axonal dystrophy and partially improved behavior phenotypes. While PGRN deficiency reduces these amyloidosis-related phenotypes, other neuronal injury mechanisms are increased by loss of PGRN, revealing a multidimensional interaction of GRN with AD. For example, C1q complement deposition at synapses is enhanced in APP/PS1 mice lacking PGRN. Moreover, PGRN deficiency increases tau AT8 and AT180 pathologies in human P301L tau-expressing mice. These human and rodent data suggest that global PGRN reduction induces microglial TNG expression and increases AD risk by exacerbating neuronal injury and tau pathology, rather than by accelerating Aß pathology.


Assuntos
Doença de Alzheimer/metabolismo , Proteínas Amiloidogênicas/metabolismo , Degeneração Lobar Frontotemporal/metabolismo , Peptídeos e Proteínas de Sinalização Intercelular/metabolismo , Placa Amiloide/metabolismo , Proteínas tau/metabolismo , Doença de Alzheimer/patologia , Amiloidose/metabolismo , Animais , Modelos Animais de Doenças , Degeneração Lobar Frontotemporal/patologia , Granulinas , Humanos , Peptídeos e Proteínas de Sinalização Intercelular/deficiência , Camundongos , Camundongos Transgênicos , Microglia/patologia , Placa Amiloide/patologia , Progranulinas
2.
Neuron ; 77(5): 859-66, 2013 Mar 06.
Artigo em Inglês | MEDLINE | ID: mdl-23473316

RESUMO

Experience rearranges anatomical connectivity in the brain, but such plasticity is suppressed in adulthood. We examined the turnover of dendritic spines and axonal varicosities in the somatosensory cortex of mice lacking Nogo Receptor 1 (NgR1). Through adolescence, the anatomy and plasticity of ngr1 null mice are indistinguishable from control, but suppression of turnover after age 26 days fails to occur in ngr1-/- mice. Adolescent anatomical plasticity can be restored to 1-year-old mice by conditional deletion of ngr1. Suppression of anatomical dynamics by NgR1 is cell autonomous and is phenocopied by deletion of Nogo-A ligand. Whisker removal deprives the somatosensory cortex of experience-dependent input and reduces dendritic spine turnover in adult ngr1-/- mice to control levels, while an acutely enriched environment increases dendritic spine dynamics in control mice to the level of ngr1-/- mice in a standard environment. Thus, NgR1 determines the low set point for synaptic turnover in adult cerebral cortex.


Assuntos
Química Encefálica/fisiologia , Encéfalo/anatomia & histologia , Proteínas da Mielina/fisiologia , Plasticidade Neuronal/fisiologia , Envelhecimento/fisiologia , Animais , Comportamento/fisiologia , Encéfalo/crescimento & desenvolvimento , Química Encefálica/genética , Córtex Cerebral/crescimento & desenvolvimento , Córtex Cerebral/fisiologia , Espinhas Dendríticas/fisiologia , Denervação , Medo/psicologia , Proteínas de Fluorescência Verde/genética , Processamento de Imagem Assistida por Computador , Camundongos , Camundongos Knockout , Camundongos Transgênicos , Microscopia Confocal , Mutação/genética , Mutação/fisiologia , Proteínas da Mielina/genética , Plasticidade Neuronal/genética , Proteínas Nogo , Equilíbrio Postural/genética , Equilíbrio Postural/fisiologia , Vibrissas/inervação
3.
Endocrinology ; 151(5): 2117-27, 2010 May.
Artigo em Inglês | MEDLINE | ID: mdl-20211972

RESUMO

Numerous clinical and experimental studies have linked stress to changes in risk factors associated with the development of physiological syndromes, including metabolic disorders. How different mediators of the stress response, such as corticosterone (CORT), influence these changes in risk remains unclear. Although CORT has beneficial short-term effects, long-term CORT exposure can result in damage to the physiological systems it protects acutely. Disruption of this important physiologic signal is observed in numerous disparate disorders, ranging from depression to Cushing's syndrome. Thus, understanding the effects of chronic high CORT on metabolism and physiology is of key importance. We explored the effects of 4-wk exposure to CORT dissolved in the drinking water on the physiology and behavior of male mice. We used this approach as a noninvasive way of altering plasma CORT levels while retaining some integrity in the diurnal rhythm present in normal animals. This approach has advantages over methods involving constant CORT pellets, CORT injections, or adrenalectomy. We found that high doses of CORT (100 microg/ml) result in rapid and dramatic increases in weight gain, increased adiposity, elevated plasma leptin, insulin and triglyceride levels, hyperphagia, and decreased home-cage locomotion. A lower dose of CORT (25 microg/ml) resulted in an intermediate phenotype in some of these measures but had no effect on others. We propose that the physiological changes observed in the high-CORT animals approximate changes observed in individuals suffering from the metabolic syndrome, and that they potentially serve as a model for hypercortisolemia and stress-related obesity.


Assuntos
Fenômenos Químicos/efeitos dos fármacos , Corticosterona/farmacologia , Sistema Endócrino/efeitos dos fármacos , Tecido Adiposo Branco/efeitos dos fármacos , Tecido Adiposo Branco/metabolismo , Adiposidade/efeitos dos fármacos , Glândulas Suprarrenais/efeitos dos fármacos , Glândulas Suprarrenais/patologia , Animais , Atrofia/induzido quimicamente , Corticosterona/sangue , Corticosterona/toxicidade , Modelos Animais de Doenças , Relação Dose-Resposta a Droga , Intolerância à Glucose/induzido quimicamente , Hiperfagia/induzido quimicamente , Insulina/sangue , Leptina/sangue , Masculino , Síndrome Metabólica/sangue , Síndrome Metabólica/induzido quimicamente , Camundongos , Camundongos Endogâmicos C57BL , Atividade Motora/efeitos dos fármacos , Timo/efeitos dos fármacos , Timo/patologia , Triglicerídeos/sangue , Aumento de Peso/efeitos dos fármacos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA